Drug Discovery World

JUNE 1, 2023

A Nature publication confirmed that there are currently 12 FDA-approved ADCs on the market, and nine of these secured FDA approval in the past six years 2. A market research report published in late June 2018 by HTF market Intelligence Consulting suggested that the ADC market in China would grow exponentially by 2023 4.

Antibody 98

Antibody Marketing Drugs Licensing 98

XTalks

NOVEMBER 9, 2023

Eli Lilly is now fully armed on the GLP-1 front as it’s finally received US Food and Drug Administration (FDA) approval for Zepbound (tirzepatide), its obesity version of Mounjaro. The FDA approved Zepbound for chronic weight management in adults with obesity.

FDA Approval 59

FDA Approval Manufacturing Drugs Pharmacy 59

XTalks

FEBRUARY 3, 2023

Until now, fulvestrant was the only other selective estrogen receptor degrader (SERD) therapy approved for ER+ breast cancer, delivered via intramuscular injections. This approval follows the promising results of the Phase III EMERALD global clinical trial published in the Journal of Clinical Oncology.

Clinical Trials 97

Clinical Trials Clinical Trials FDA Approval Trials 97

XTalks

FEBRUARY 5, 2024

The top 40 best-selling oncology drugs in 2023, informed by 2022 sales statistics, mark significant milestones in cancer treatment and research. In the dynamic landscape of oncology therapeutics, understanding the trends and performances of leading drugs is crucial for stakeholders across the healthcare and life sciences sectors.

FDA Approval 101

FDA Approval Drugs Sales Development 101

The Pharma Data

MAY 13, 2021

But I’ve been a long time researcher passionate to help people all over the world on how to live better lives and spread awareness on how anyone can help support a healthy weight loss. Well, sleep keeps the “hunger hormones” (ghrelin and leptin) in check. Well, sleep keeps the “hunger hormones” (ghrelin and leptin) in check.

Hormones 52

Hormones Production Packaging Packaging 52

XTalks

FEBRUARY 5, 2024

The top 40 best-selling oncology drugs in 2023, informed by 2022 sales statistics, mark significant milestones in cancer treatment and research. In the dynamic landscape of oncology therapeutics, understanding the trends and performances of leading drugs is crucial for stakeholders across the healthcare and life sciences sectors.

FDA Approval 52

FDA Approval Drugs Sales Development 52

Delveinsight

AUGUST 2, 2020

Cachexia is observed as a result of underlying diseases, including cancer, AIDS, tuberculosis, chronic heart failure, hormonal deficiency, and others. According to research conducted by Von Haehling S et al., The disorder renders the affected person immunocompromised unable to fight against infection.

Marketing 94

Marketing Pharma Companies Development Hormones 94

XTalks

JUNE 27, 2022

Novartis’ Tafinlar and Mekinist received FDA approval for the treatment of unresectable or metastatic solid tumors with the BRAF V600E mutation. These types of treatments represent the goal of precision medicine , where therapies are tailored to specific patient types. Tafinlar and Mekinist Combination Clinical Trial Results.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Regulation 52

Pfizer

JANUARY 27, 2023

Pfizer Responds to Research Claims carterda Fri, 01/27/2023 - 19:48 Pfizer Responds to Research Claims Friday, January 27, 2023 - 08:00pm Share New York, N.Y., In the ongoing development of the Pfizer-BioNTech COVID-19 vaccine, Pfizer has not conducted gain of function or directed evolution research.

Research 112

Research Vaccination Vaccine Drugs 112

The Pharma Data

AUGUST 30, 2021

Roche made this decision following consultation with the US FDA, based on the agency’s assessment of the current mTNBC treatment landscape and in accordance with the requirements of the accelerated approval programme. This is not related to any changes in either the efficacy or safety associated with Tecentriq.

Medicine 52

Medicine Antibody Hormones FDA Approval 52

pharmaphorum

DECEMBER 23, 2020

It has been a year dominated by the pandemic and many life sciences research projects were put on hold as big pharma turned its attention to vaccines and therapies. But there was some considerable progress in other fields of medicine even though research efforts were diverted away, reports Richard Staines. Rare disease progress.

Marketing 73

Marketing Gene Silencing Gene Drugs 73

The Pharma Data

JUNE 24, 2021

The prognosis for men with advanced prostate cancer has significantly improved since the introduction of novel hormone therapies, but additional therapeutic options are needed for the approximately 25 percent of men with tumors harboring DNA damage response (DDR) gene mutations, who may have poorer outcomes,” said Chris Boshoff, M.D.,

DNA 52

DNA Clinical Trials Clinical Trials Trials 52

XTalks

MAY 17, 2023

Astellas Pharma recently announced the US Food and Drug Administration (FDA) approval of their new medication, Veozah (fezolinetant) for the treatment of moderate to severe hot flashes and night sweats due to menopause. Hormone replacement therapy is thought to be one of the most effective treatments for vasomotor symptoms.

Hormones 95

Hormones FDA Approval Drugs Clinical Trials 95

The Pharma Data

APRIL 27, 2021

Today’s ODAC meeting is part of an industry-wide review of accelerated approvals with confirmatory trials that have not met their primary endpoint(s) and have yet to gain regular approvals. “We 1 TNBC represents ~15% of all breast cancers and is more common in women under the age of 50, compared with other forms of breast cancer.

Medicine 40

Medicine In-Vitro Antibody Development 40

XTalks

AUGUST 10, 2022

In the US, it is estimated that 287,850 new cases of female breast cancer will be diagnosed in 2022, according to data from the National Cancer Institute (NCI) outlined by the FDA. The trial included 494 hormone receptor positive (HR+) patients and 63 hormone receptor negative (HR-) patients. Cancer Moonshot Program.

FDA Approval 98

FDA Approval HR Hormones Antibody 98

The Pharma Data

FEBRUARY 8, 2021

“The TITAN final analysis data confirm the long-term clinical benefit and consistent safety profile of ERLEADA ® plus ADT without a compromise in health-related quality of life,” said Mary Guckert, RN, MSN, Vice President, Development Leader, Prostate Cancer, Janssen Research & Development, LLC. About ERLEADA ® (apalutamide).

HR 52

HR Hormones Development Production 52

The Pharma Data

AUGUST 17, 2021

Also tell your doctor: about all of the medicines you take, including over-the-counter medicines, vitamins, and herbal supplements. about any other prescription medicines you take, especially ones called TZDs. drink alcohol or use other medicines that contain alcohol when taking your Lyumjev or Humalog. Before using.

Insulin 52

Insulin FDA Approval Doctors Doctor 52

XTalks

FEBRUARY 7, 2023

The FDA approval is an important step forward for both women and men living with metastatic breast cancer, especially for those individuals whose tumor is no longer responding to endocrine-based therapies and who are facing a poor prognosis,” said Laura Carfang, executive director, SurvivingBreastCancer.org, in the press release.

HR 52

HR Hormones FDA Approval Antibody 52

XTalks

APRIL 29, 2022

Tirzepatide is a novel investigational obesity treatment that contains mimetics of two hormones that are involved in regulating appetite in a single peptide: a GIP (glucose-dependent insulinotropic polypeptide) receptor agonist and a GLP-1 (glucagon-like peptide-1) receptor agonist. percent and 22.5 percent, respectively, compared to placebo.

Trials 98

Trials Drugs FDA Approval Clinical Trials 98

The Pharma Data

JULY 22, 2021

Gregory Lubiniecki, Vice President, Oncology Clinical Research, Merck Research Laboratories. Based on the type and/or severity of the adverse reaction, LENVIMA may be interrupted, reduced and/or discontinued.

HR 52

HR Trials Dermatology Hormones 52

XTalks

AUGUST 2, 2023

With each passing year, pharmaceutical companies around the globe strive to deliver cutting-edge medicines, therapies and vaccines that impact the lives of millions. In this in-depth article, we embark on a captivating journey to uncover the top 30 pharma and biotech companies that have been instrumental in shaping the future of medicine.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

AUGUST 3, 2021

billion in acquired in-process research & development (acquired IPR&D) associated with our acquisition of Five Prime Therapeutics, partially offset by increased revenues. pts Research & Development $ 1,082 $ 964 12% $ 1,036 $ 936 11% % of product sales 17.7% GAAP earnings per share (EPS) decreased 73% to $0.81 39.3% (25.8)

Sales 52

Sales Production Antibody Development 52

The Pharma Data

APRIL 4, 2023

The combination therapy was granted Breakthrough Therapy designation by the FDA in February 2020. confirmatory trial for the accelerated approval. Merck has the industry’s largest immuno-oncology clinical research program. Initiate hormone replacement as indicated. Withhold KEYTRUDA depending on severity.

FDA Approval 40

FDA Approval Containment Hormones Dermatology 40

The Pharma Data

JUNE 18, 2021

IMBRUVICA is the only FDA-approved medicine in WM and cGVHD. IMBRUVICA was one of the first medicines to receive FDA approval via the Breakthrough Therapy Designation pathway. IMBRUVICA was one of the first medicines to receive FDA approval via the Breakthrough Therapy Designation pathway.

Medicine 40

Medicine Production FDA Approval Trials 40

The Pharma Data

APRIL 7, 2021

Prior to the FDA approval of Trodelvy, patients with previously treated metastatic TNBC had few treatment options in this high unmet-need setting. The FDA granted accelerated approval to Trodelvy in April 2020 based on objective response rate and duration of response results in a Phase 1/2 study. About the ASCENT Study.

HR 52

HR Genotype FDA Approval Genotoxicity 52

The Pharma Data

JUNE 18, 2021

. “With CLL being one of the most common types of blood cancer, the expansion of research into additional treatment options for patients is an important clinical undertaking,” said Arnon Kater , M.D., deputy head of hematology, University of Amsterdam Faculty of Medicine. About VENCLEXTA ® /VENCLYXTO ® (venetoclax).

Medicine 52

Medicine Production FDA Approval Trials 52

The Pharma Data

JANUARY 4, 2021

We have been researching TIGIT as a novel cancer immunotherapy target for almost 10 years and we are pleased that the FDA has acknowledged the potential of tiragolumab to substantially improve outcomes for people with certain types of lung cancer,” said Levi Garraway, M.D., chief medical officer and head of Global Product Development.

Immune Response 52

Immune Response Medicine Protein Gene 52

XTalks

DECEMBER 22, 2021

percent, according to a report by BCC Research. In attempts to mask RNA from immune attack, researchers Drew Weissman and Katalin Karikó at the University of Pennsylvania switched out uridine, which is one of the four bases of the RNA code, for pseudouridine. billion by 2026 at a compound annual growth rate (CAGR) of 16.8

Life Science 98

Life Science RNA Vaccination Vaccine 98

Intouch Solutions

AUGUST 5, 2021

This then leads many of those same people to online forums like the TransDIY subreddit that’s dedicated to do-it-yourself hormone replacement therapy, or DIY HRT. DIY HRT is a combination of non-prescribed, often unregulated, hormone medicines and self-performed surgeries that are administered without the supervision of an HCP.

Marketing 52

Marketing Doctors Doctor Clinical Trials 52

The Pharma Data

JUNE 18, 2021

lead study investigator of the Phase 3 RESONATE-2 trial, and Professor of Medicine at the Wilmot Cancer Institute, University of Rochester. IMBRUVICA ® is the only FDA-approved medicine in WM and cGVHD. IMBRUVICA ® was one of the first medicines to receive FDA approval via the Breakthrough Therapy Designation pathway.

FDA Approval 40

FDA Approval Medicine Development Trials 40

The Pharma Data

JULY 23, 2021

The goal of the company’s cancer research is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility. 1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Thyroiditis can present with or without endocrinopathy.

Hormones 52

Hormones Trials Genome Genomics 52

The Pharma Data

FEBRUARY 8, 2021

Vice President, Late Development and Global Medical Affairs, Oncology, Janssen Research & Development, LLC. “In In our commitment to advance the science and treatment of prostate cancer, these findings will help inform our research efforts in developing novel approaches and combinatory regimens to improve outcomes for these patients.”.

HR 52

HR In-Vitro Development Clinical Trials 52

The Pharma Data

MARCH 11, 2021

The goal of the company’s cancer research is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility. 1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Thyroiditis can present with or without endocrinopathy.

Trials 52

Trials Hormones Genome Genomics 52

The Pharma Data

AUGUST 11, 2020

Bristol Myers Squibb: Advancing Cancer Research. The goal of our cancer research is to increase patients’ quality of life, long-term survival and make cure a possibility. 1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. About Opdivo.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

The Pharma Data

AUGUST 11, 2020

Bristol Myers Squibb: Advancing Cancer Research. The goal of our cancer research is to increase patients’ quality of life, long-term survival and make cure a possibility. 1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. About Opdivo.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

The Pharma Data

JUNE 28, 2021

Medical Director, National Research Institute and Principal Investigator of SURPASS-2. Injectable semaglutide 1 mg is a GLP-1 receptor agonist and the highest dose of injectable semaglutide FDA-approved for the treatment of type 2 diabetes. GIP is a hormone that may complement the effects of GLP-1.

Insulin 52

Insulin Clinical Trials Clinical Trials Hormones 52

The Pharma Data

MAY 4, 2021

Internal Medicine. The findings represent the first comprehensive comparative effectiveness analysis of survival outcomes for a CDK 4/6 inhibitor in routine clinical practice and were published online in Breast Cancer Research. The FDA action converts the 2018 accelerated approval to full approval. 1,611. . *. *.

Vaccination 40

Vaccination Vaccine Production Sales 40